Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Nick Duncan

Nick Duncan is principal pharmacist in haematology and oncology at University Hospitals Birmingham NHS Foundation Trust.

Recent stories

  • Micrograph of multiple myeloma tumour cells (green) and bone cells (red) growing on a scaffold made of silk protein (purple), designed to resemble bone material

    Multiple myeloma: pharmacological management

    9 MAR 2017

    Although multiple myeloma is currently regarded as being incurable in the majority of patients, the outlook for patients diagnosed with the condition has improved markedly over the last 40 years, with survival rates quadrupling. Significant advances in both treatment and supportive therapies have contributed to these improved outcomes and are discussed in this article.

  • Hodgkin lymphoma and non-Hodgkin lymphoma treatment is based on combination chemotherapy

    Lymphomas: current and future treatment optionsSubscription

    24 OCT 2014Comments (1)

    The management of lymphomas involves a range of different chemotherapy schedules, with novel medicines emerging and offering better treatment options.

  • Treatment for multiple myeloma, harvesting bone marrow for use in transplant

    Multiple myeloma: managementSubscription

    CP, 2012

    Treatment for multiple myeloma aims to control the disease, maximise quality of life and prolong survival; this can be achieved through a combination of disease-specific therapies and supportive care

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.